Bold, meaningful collaborations. It’s critically important that we get them right because our work has the potential to impact the lives of millions. With more than 100 business development transactions since 2015, our team has the experience of working with a broad range of partners through a wide spectrum of collaborations from early-stage science to clinical-stage programs. Whether your innovation is from academia or a biotechnology company, you will find our process to be rapid, clear and straightforward. We believe that by working together we can play a major role in transforming global health care. Together we can invent for life.
“We understand how difficult the path from bench to bedside is, what may work and what may not. We strive to be an exemplary collaborator - working side-by-side, tackling the tough issues that arise towards a shared mission of bringing important new medicines to patients.”
“It is our job to not only know which companies and academic centers are making real advances, but also to track great science with the potential to address critical unmet needs. Merck is excited about collaborating with our current and future partners.”
“Merck has a long tradition of successful partnerships. Our partnering process is rapid, clear, straightforward and flexible. Our goal is to craft a structure that serves the needs of all parties and ultimately benefits patients.”
“ BD&L IS MORE THAN LICENSING AND ACQUISITIONS ”
Written by Kanad Das,
director, West Coast Business Development & Licensing
Oncology and Immuno-Oncology
Infectious Disease and Vaccines
INCYTE: IN THE RACE AGAINST CANCER
After the first positive signals emerged from the phase I/II trial evaluating the combination of Incyte's selective IDO1 inhibitor with Merck's PD-1 inhibitor, Incyte and Merck moved quickly into a phase III study. And now, the first patients with treatment-naïve advanced melanoma are being treated in the pivotal ECHO-301/Keynote-252 phase III study.
MODERNA: HARNESSING A BOLD, NEW MODALITY
Moderna is pioneering the development of novel drugs using messenger RNA (mRNA). Together, we are striving to advance transformative new vaccines and therapies for viral diseases and cancer
NGM BIO: TRANSFORMING THE FUTURE
Merck is supporting not just one, but multiple drug candidates from NGM’s innovative drug discovery engine. And to provide NGM with what they need to pursue their ambitious R&D goals and thrive, they have full research autonomy allowing them the freedom to follow their scientific instincts.
GREAT DRUGS BEGIN WITH A GREAT CONVERSATION.
We’re ready to have meaningful discussions about your work and your perspective. You’ll find us ready to listen because we believe that building strong external alliances is one of the most important jobs we have. Our Business Development & Licensing organization is comprised of experts in their fields who are ready to work with you — including teams based in key epicenters of biomedical innovation (Boston, West Coast, Europe, Asia Pacific and Japan).
Meet our BD&L team at an upcoming event
CED Life Science Conference
Raleigh, North Carolina
BIOCOM Global Life Science Partnering Conference
La Jolla, California
FEBRUARY 27 - MARCH 1
American College of Cardiology Annual Scientific Session
American Association Cancer Research (AACR) Annual Meeting
Association Research Vision & Ophthalmology (ARVO) Annual Meeting
APRIL 29 - MAY 3
New York BIO Annual Conference
New York, New York